Application and Efficacy Analysis of Ulinastatin in Treating Acute Poisoning with Respiratory Failure in Athletic Patients by Hemoperfusion

Abstract

Objective: This study aims to assess the clinical efficacy of ulinastatin in conjunction with hemoperfusion for treating athletic patients suffering from acute poisoning accompanied by respiratory failure. Methods: A total of 36 athletic patients diagnosed with acute poisoning and subsequent respiratory failure were selected for this study. They were divided into two groups: the control group (n=18) received standard treatment plus hemoperfusion, while the ulinastatin group (n=18) was treated with additional ulinastatin on top of the control group's regimen. The primary outcomes measured included the 21-day mortality rate and various clinical indices post-admission. Furthermore, the study evaluated changes in lung function, levels of inflammatory and oxidative stress markers, and renal function indices, in addition to documenting any adverse reactions during treatment. Results: The study found that the mortality rates for the ulinastatin and control groups were 5.56% (1/18) and 33.33% (6/18), respectively, though the difference was not statistically significant (P > 0.05). Notably, the combination of ulinastatin with hemoperfusion resulted in a quicker recovery of spontaneous breathing and consciousness, shorter hospital stays, and a reduction in disease severity among athletic patients. This treatment approach also led to improvements in forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and the FEV1/FVC ratio, alongside reductions in inflammatory and oxidative stress markers, and enhancements in blood gas analysis results. No severe adverse reactions were observed in either group. Conclusion: The incorporation of ulinastatin with hemoperfusion for the treatment of acute poisoning complicated with respiratory failure in athletic patients appears to significantly enhance inflammation and oxidative stress response, while also mitigating lung and renal dysfunction. This suggests that ulinastatin, alongside hemoperfusion, could be a valuable addition to the treatment regimen for athletes experiencing severe poisoning, contributing to better overall outcomes and quicker return to physical activity.